Published in final edited form as:

Psychiatry Res. 2014 August 15; 218(0): 201–208. doi:10.1016/j.psychres.2014.04.015.

The concomitant use of second generation antipsychotics and long term antiretroviral therapy may be associated with increased cardiovascular risk

Maria Ferrara^{*,a,b}, Anya Umlauf^b, Chelsea Sanders^b, Jonathan M. Meyer^{c,d}, J. Allen McCutchan^b, Nichole Duarte^b, J. Hampton Atkinson^{d,b}, Igor Grant^b, Ronald J. Ellis^b, and The CHARTER Group

^aDepartment of Mental Health, AUSL Modena, Modena, Italy

^bHIV Neurobehavioral Research Program (HNRP), University of California, San Diego (UCSD), 220 Dickinson Street, Suite B, San Diego, CA 92103-8231, USA

^cDepartment of Psychiatry, University of California, San Diego (UCSD), 9500 Gilman Drive, La Jolla CA 92093-0603, USA

^dPsychiatry Service, VA San Diego Healthcare System, 3350 La Jolla Village Drive (116-A), San Diego, CA, 92161

Abstract

To study the effect of concurrent use of second-generation antipsychotics (SGAs) on metabolic syndrome components conferring increased cardiovascular risk in a sample of HIV-infected adults taking ART. A retrospective study of participants consecutively recruited at the UCSD HIV Neurobehavioral Research Program examined effects of combined ART and SGAs on body mass index (BMI), nonfasting serum lipids, diabetes mellitus (DM) incidence, and mean arterial pressure (MAP). Metabolic outcome variables and covariates were compared using t-tests, Chi-squared or Fisher's exact tests. Linear and logistic multivariable models explored metabolic outcomes for participants taking (SGA+) or not taking (SGA-) concomitant SGAs, after controlling for demographic and HIV disease- and ART-related covariates. Of 2229 HIV-infected participants, 12% ($N=258$) were treated with SGAs. In multivariable models adjusted for relevant covariates, the SGA+ group had significantly higher mean triglycerides, significantly higher odds of DM, significantly higher mean arterial pressures and marginally higher BMI. Use of SGAs in HIV-infected adults taking ART was independently associated with worse indicators of metabolic syndrome and cardiovascular risk. Aggressive monitoring for the metabolic complications from concurrent SGA and ART is indicated in all patients receiving these medication combinations.

© 2014 Elsevier Ireland Ltd. All rights reserved.

Corresponding author: Maria Ferrara, Department of Mental Health, AUSL Modena, Via S. Giovanni del Cantone, 23, 41121 Modena, Italy, Tel +39 059 435970, Fax +39 059 435800, maria.ferrara@live.it.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

HIV; cardiovascular risk; serious mental illness; diabetes mellitus; obesity; hypertriglyceridemia; hypertension

1. Introduction

Psychiatric disorders are more prevalent in human immunodeficiency virus (HIV) infected people than in the general population (Atkinson et al., 1988; Atkinson et al., 2008; Bing et al., 2001; Cournos and McKinnon, 1997; Gaynes et al., 2008; Rabkin, 2008). Prevalence of HIV infection among persons with serious mental illness (SMI) is estimated to be between 3% and 23%, or more than 10 fold higher than the 0.4% in the general United States population (Cournos and McKinnon, 1997; Lee et al., 2011; Meyer, 2003). Due to the high SMI prevalence in this population, psychotropic medications are commonly used by HIV-infected patients (Bing et al., 2001; Gaynes et al., 2008; Thompson et al., 2006; Vitiello et al., 2003; Walkup et al., 2004). Data from the US Medicaid population obtained from July 2002 through June 2003 showed that 89% of HIV-infected people with SMI used psychotropic medications (Lee et al., 2011).

Antipsychotics are commonly employed for patients with SMI, in part due to the broad array of FDA-approved indications for antipsychotics in adults, including the acute and maintenance treatment of schizophrenia, acute mania, maintenance treatment in bipolar disorder and adjunctive therapy for major depressive disorder (Meyer, 2010). While both older “typical” and the newer “atypical” medications (second generation antipsychotics or SGAs) are widely used, SGAs have a therapeutic advantage due to a lower incidence of extrapyramidal symptoms (Meyer, 2010). Though SGA use has steadily increased due to this improved neurological tolerability and the availability of multiple generic drugs in this class, the enthusiasm for certain SGAs has been tempered by their association with metabolic abnormalities (e.g. hyperglycemia, weight gain, and hyperlipidemia) (Stahl et al., 2009) and an increased prevalence of metabolic syndrome (MetS) (Meyer and Stahl, 2009). Metabolic syndrome (MetS) is a constellation of frequently concurrent conditions, including central obesity, atherogenic dyslipidemia, hypertension, glucose intolerance/diabetes (DM) and a prothrombotic/inflammatory state, that increase the risk of cardiovascular and cerebrovascular disease (Girman et al., 2005; Wannamethee et al., 2005). Greater numbers of MetS components predict higher risk for myocardial infarction and stroke (Girman et al., 2005; Wannamethee et al., 2005). Whether due to treatment or inherent biological factors associated with SMI, MetS prevalence is 2–3 times greater in persons with schizophrenia or bipolar disorder compared to the general population (McEvoy et al., 2005), and thus represents an important source of increased cardiovascular risk.

In addition to possible biological variables related to the diagnosis of SMI itself, SMI patients also have a higher prevalence of behavioral factors (smoking tobacco, poor dietary habits, and inactivity) that amplify the risk of cardiovascular mortality compared to age-matched peers without SMI (Meyer, 2010), and higher rates of medical comorbidity noted at the time of diagnosis before exposure to antipsychotics (Meyer, 2010). Subsequent exposure to SGAs may therefore increase the risk of cardiovascular mortality for SMI patients as

suggested by the increasing relative risk of cardiovascular mortality in SMI patients during the SGA era (Colton and Manderscheid, 2006; De Hert et al., 2009; Saha et al., 2007).

The development of metabolic adverse effects is not unique to SGAs, with an extensive literature documenting the impact of combination antiretroviral therapy (cART) for HIV on lipids, weight and cardiovascular risk. While cART markedly reduces mortality due to HIV infection, it is also associated specifically with increased prevalence of metabolic syndrome (MetS) (25% to 96%) (Carr, 2003; Falutz, 2007; Feeney and Mallon, 2011; Germinario, 2003). Despite the high rates of HIV and psychiatric comorbidity, and the known metabolic effects of SGAs and antiretrovirals, the metabolic consequences of SGA exposure in HIV-infected individuals has received virtually no coverage in the literature (Singh and Goodkin, 2007). This study attempts to address the gap in the clinical understanding of the metabolic impact of SGA use in HIV patients.

2. Methods

2.1 Study design

This retrospective, cross-sectional study examined metabolic outcomes in 2229 antiretroviral-treated, HIV-infected adults.

2.2. Subjects

Participants were HIV-infected volunteers consecutively recruited for clinical studies at the UCSD HIV Neurobehavioral Research Program (HNRP) in San Diego, California, between January 1995 and September 2011. Participants were enrolled in various studies sponsored by the National Institute of Mental Health and the National Institute on Drug Abuse including 1097 from “The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER)” Study, 255 from “The California NeuroAIDS Tissue Network (CNTN)”, 195 from “NeuroAIDS: Effects of Methamphetamine and Hepatitis C Virus”, 179 from “Prospective Memory and HIV Infection (PROM)” and 509 from smaller HNRP studies.

Inclusion criteria were serologically documented HIV infection, age ≥ 18 years, current treatment with antiretroviral therapy (ART) and adequate documentation of concomitant medication use. Because the HNRP studies HIV-associated neurocognitive disorders, volunteers with conditions that prevented individuals from undergoing detailed neuropsychological testing (eg, acute psychosis) or might confound assessment of specific HIV-related brain disorders were excluded (e.g., type I diabetes mellitus and schizophrenia, since the former can be associated with micro-vascular disease of the brain and neurocognitive impairment, and schizophrenia is a neurodevelopmental disorder with deficits in executive function, among other impairments). All subjects completed structured medical, psychiatric, and laboratory assessments. Duration of treatment with ARTs and SGAs was collected through standardized case report forms by trained research nurses. For the purpose of this study we selected data from the participant’s most recent visit.

Protocols were approved by the Institutional Review Boards of participating institutions. Written informed consent was obtained from all study participants before enrollment.

2.3 Clinical evaluation and laboratory measures

Standardized general medical histories and physical examinations were performed, and blood pressure measurements obtained using automated calibrated mercury sphygmomanometers with appropriate cuff sizes. Systolic (SBP) and diastolic (DBP) measures were obtained from seated subjects to calculate mean arterial pressure (MAP). Height and weight for calculating body mass index (BMI) were measured. A diagnosis of diabetes mellitus was ascertained according to the Expert Committee on the Classification of Diabetes (Expert Committee on the and Classification of Diabetes, 2003; Genuth et al., 2003). Venipuncture for non-fasting laboratory studies was performed at the time of the visit. After clotting, serum was assayed for total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), serum triglycerides (TG) and glucose. Total cholesterol was dichotomized as high (> 200 mg/dL) or normal, HDL-cholesterol values as low (< 40 mg/dL) or normal; the ratio of TC/HDL-cholesterol was also calculated (TC/HDL). Hepatitis C virus (HCV) serology (HCV Antibody essay: LabCorp, Burlington, North Carolina) was examined because of the association of chronic HCV infection with DM (Mehta et al., 2000), insulin resistance (Romero-Gomez, 2006), impaired lipid metabolism (Lonardo et al., 2004; Negro and Sanyal, 2009) and MetS (Grigorescu et al., 2008).

2.4 Characterization of HIV infection

A detailed history of HIV illness and treatment was captured by a combination of questionnaires and standardized interview. Nadir CD4 cell count since HIV infection was self-reported. Past and current antiretroviral usage including usage dates, dose, and schedule for each drug were captured by self-report standardized questionnaires that were reviewed with clinicians. Antiretroviral (ART) exposure was categorized as current use, past use, or never used. ART regimens were dichotomized as 1) protease inhibitor (PI) based vs. non-PI based (Nolan, 2003); and 2) Efavirenz (EFV) based vs. non-EFV based (Haubrich et al., 2009). Blood CD4 cell counts were measured by flow cytometry. HIV RNA levels were quantified in plasma and cerebrospinal fluid (CSF) by reverse transcriptase-polymerase chain reaction (Amplicor®, Roche Diagnostic Systems, Indianapolis, IN) using an ultrasensitive assay (lower quantification limit < 50 copies/mL).

2.5 Psychiatric diagnoses and prescribed second-generation antipsychotics

Depending on specific protocols, psychiatric diagnoses were assessed using either the Composite International Diagnostic Interview (CIDI) (Robins et al., 1988), the Psychiatric Research Interview for Substance and Mental Disorders (PRISM) (Hasin et al., 1996), or the Structured Clinical Interview for DSM-IV criteria (SCID IV) (Spitzer et al., 1992). Each of these assessments included modules for diagnosis of mood disorder, alcohol use disorders, and non-alcohol substance use disorders using DSM-IV criteria. Participants in the antipsychotic exposed group (SGA+) reported current use of one or more of the following SGAs: aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone.

2.6 Statistical analysis

Two groups (SGA– and SGA+) were compared on demographic, HIV-associated, and psychiatric characteristics, using two-sample t-test and Chi-square test for continuous and categorical variables, respectively. Two sample t-tests and Chi-square tests were also performed to analyze the effect of SGA use on eight metabolic variables: BMI, MAP, TC, HDL cholesterol, LDL cholesterol, TC/HDL ratio, triglycerides and DM. Additionally, TC and TG values were also analyzed on a dichotomized scale based on the most recent guidelines for risk ranges: TC $\geq$ 200 mg/dL, HDL $<$ 40 mg/dL, LDL $\geq$ 130 mg/dL, TC/HDL $\geq$ 5, TG $\geq$ 150 mg/dL (Blackburn et al., 2008; Lemieux et al., 2000; Mannucci et al., 2008). Since each metabolic outcome was analyzed separately, we used all data available for each outcome to maximize the power of each analysis. Thus, sample sizes for regressions varied for each variable. HIV RNA levels were $\log_{10}$ transformed and analyzed both continuously and categorically, as undetectable vs. detectable.

Effects of individual SGAs on the metabolic outcomes were evaluated in a series of univariable analyses using the methods described above. In addition, outcomes were tested for an association with treatment duration of each SGA using Spearman correlation or logistic regression.

Use of individual ART medications in the SGA+ group was compared to that in SGA– group using the Chi-square test (or Fisher's exact test, if appropriate). The effects of PIs with known metabolic risks on the metabolic outcomes in this study were evaluated with t-tests (or Wilcoxon rank-sum test) and Chi-square test (or Fisher's exact test).

Multivariable analysis was performed for every metabolic outcome to control for the effects of covariates. Linear and logistic regressions were used to analyze continuous and categorical outcomes, respectively. Power transformations were applied to selected outcomes to achieve normally distributed residuals. The following sixteen covariates were tested for association with each outcome in a series of univariable regressions: age, sex, ethnicity, HCV co-infection, estimated duration of HIV infection, CD4 nadir, current CD4, detectable plasma viral load (VL), duration of current ART regimen, PI-based regimen, EFV use, current major depressive disorder and lifetime alcohol and other substance dependence diagnosis. Each multivariable model initially included SGA group indicator (SGA+/SGA–) and those covariates that showed an association with an outcome at 0.20 significance level (Vittinghoff et al., 2005). Model selection processes, using Akaike Information Criterion (AIC), were applied to reduce each model to include only the SGA group indicator and covariates significant at the $P=0.10$ level. Effect sizes (ES) and their 95% confidence intervals were calculated for each univariable (unadjusted) and multivariable model predicting a metabolic outcome. In linear regressions, the ES was measured as difference in means standardized by residual standard deviation (Cohen's d). Odds ratios (OR) were used to quantify the ES for logistic regressions.

The analyses were carried out using the statistical software R version 2.10.0 (www.r-project.org). All tests were two-sided and used a significance level of 0.05, except where specified otherwise.

3. Results

Demographic, anthropometric and metabolic variables for 2229 HIV infected individuals, categorized according to their current use of SGAs, are presented in Table 1. The sample was predominantly white (47%) and male (81% of total sample), with a mean age of 45 years. The SGA+ group ($N=258$) comprised 12% of the total sample and included higher proportions of women (25% vs. 18%) and African-Americans (40% vs. 31%) than the SGA- group.

Most participants had longstanding HIV infection and low nadir CD4 counts (median 117 cells/mm³). They had taken their current antiretroviral regimen for over one year, with good virologic control and immune reconstitution based on high current CD4 counts (median 436 cells/mm³). The SGA+ and SGA- groups did not differ significantly in current and nadir CD4 cell counts, plasma viral loads or duration or composition of current ART regimen. About two-thirds were on a PI-based regimen, which in the majority of cases was boosted with ritonavir (RTV) (54% of SGA- and 59% of SGA+); EFV-based regimens were less common in SGA+ group compared to SGA- (see Supplemental Table). The two SGA groups did not differ in use of specific antiretrovirals known for causing more pronounced metabolic side effects (stavudine [D4T], ritonavir [RTV], zidovudine [ZDV], indinavir [IDV]) (Grunfeld and Feingold, 1992).

In univariate analyses, subjects in the SGA+ group had higher BMI (27.3 vs. 26.2; $t=2.9$; $P=0.004$) and a higher proportion of obese subjects (27% vs. 18%; $\chi^2=10.9$, $df=1$, $P=0.001$). SGA+ subjects also were more likely than SGA- to have diabetes mellitus (15% vs. 9%; $\chi^2=5.0$, $df=1$, $P=0.025$). SGA+ and SGA- subjects exhibited no significant differences in mean lipid fractions (TC, HDL, LDL, TG), or mean arterial blood pressure.

Numerous variables explained part of the variance in the metabolic outcomes including age, gender, ethnicity, HCV status, CD4 counts, type of ART, and specific psychiatric comorbidities such as lifetime substance dependence diagnosis. Table 3 shows the results of multivariate analyses adjusting for demographic and disease covariates. SGA+ participants had significantly higher MAP (ES=0.28, 95% CI=0.08–0.49, $P=0.006$), serum triglycerides (ES=0.28, 95% CI=0.06–0.50, $P=0.014$) and diabetes prevalence (OR=2.28, 95% CI=1.29–4.02, $P=0.004$) than SGA- subjects. In addition, SGA+ participants had non-significantly higher BMI (ES=0.16, 95% CI=–0.01–0.33, $P=0.068$). When exposure to antiretrovirals known to be associated with metabolic side effects (RTV, d4T, ZVD, IDV) was added to the models, the results of multivariable analyses did not differ significantly from those reported in Table 3. The two groups had similar TC and lipid subfractions (data not shown).

Of the 258 SGA+ participants the vast majority (> 90%) were prescribed only one SGA. The most commonly prescribed SGA was quetiapine (57%), followed by risperidone (25%), olanzapine (24%), aripiprazole (14%), ziprasidone (6%), clozapine (1%) and paliperidone (1%). The median exposure of the current SGA regimen was 15 months.

Secondary analyses examined differences between individual SGA exposure and metabolic variables. Compared to the SGA- group, quetiapine users showed significantly greater BMI (27.4 vs. 26.2 kg/m², $t=-2.03$, $P=0.044$) and a higher proportion of DM (17% vs. 9%,

$\chi^2=5.42$, $df=1$, $P=0.02$). Odds of TC/HDL ratio >5 increase with longer exposure to quetiapine (OR=1.27, 95% CI=1.06–1.53, $P=0.009$). Compared to SGA– group, risperidone users had significantly higher cholesterol levels, (196.7 vs. 182.6 mg/dL, $t=-2.02$, $P=0.044$) and proportion of people with TC level ≥ 200 mg/dL (48% vs. 31%, $\chi^2=4.83$, $df=1$, $P=0.028$). However, among those on risperidone, longer exposure to the drug was associated with lower TC levels ($r=-0.33$, $P=0.037$), lower odds of HDL < 40 mg/dL (OR=0.71, 95% CI=0.52–0.98, $P=0.035$), lower TC/HDL ratio ($r=-0.41$, $P=0.026$), lower odds of TC/HDL ratio ≥ 5 (OR=0.77, 95% CI=0.57–1.04, $P=0.084$), lower LDL ($r=-0.46$, $P=0.017$), and higher odds of diabetes (OR=1.96, 95% CI=1.03–3.74, $P=0.042$). Individuals taking aripiprazole had higher BMI (28.3 vs. 26.2 kg/m², Wilcoxon W=19019, $P=0.024$) than those not prescribed a second generation antipsychotic. Those on olanzapine had a larger proportion with triglycerides ≥ 150 mg/dL compared to the SGA– group but this difference was not statistically significant (71% vs. 56%, $\chi^2=2.84$, $df=1$, $P=0.092$).

Analysis of ART effects on metabolic outcomes showed that RTV was associated with significantly lower mean diastolic BP (75.8 vs. 77.6 mm Hg, $t=3.68$, $P<0.001$) and lower MAP (92.6 vs. 93.9 mm Hg, $t=2.57$, $P=0.01$), lower mean (sqrt) HDL cholesterol (6.65 vs. 6.84 mg/dL, $t=2.92$, $P=0.004$), higher proportion of people with HDL < 40 (44% vs. 38%, $\chi^2=7.34$, $df=1$, $P=0.007$), higher mean (log₁₀) TC/HDL ratio (0.62 vs. 0.6, $t=-2.22$, $P=0.027$), higher proportion of people with TC/HDL ≥ 5 (32% vs. 27%, $\chi^2=4.96$, $df=1$, $P=0.026$), higher mean (log₁₀) triglycerides (2.25 vs. 2.19, $t=-4.64$, $P<0.001$), and higher proportion of people with triglycerides ≥ 150 mg/dL (60% vs. 53%, $\chi^2=11.39$, $df=1$, $P<0.001$).

Among the other ARTs, d4T use was associated with significantly higher mean diastolic BP (79.6 vs. 76.5 mm Hg, $t=-2.82$, $P=0.005$), and marginally higher mean MAP (95.2 vs. 93.1 mm Hg, $t=-1.78$, $P=0.075$), while ZDV was associated with significantly lower average systolic BP (124.5 vs. 126.6 mm Hg, $t=2.42$, $P=0.016$), higher mean (log₁₀) triglycerides (2.25 vs. 2.22, $t=-2.34$, $P=0.019$), higher proportion of people with triglycerides ≥ 150 mg/dL (62% vs. 55%, $\chi^2=4.58$, $df=1$, $P=0.032$), and higher proportion of diabetes (14% vs. 9%, $\chi^2=5.70$, $df=1$, $P=0.017$). IDV use was also strongly associated with diabetes (54% vs. 10%, Fisher's exact $P<0.001$).

A diagnostic psychiatric examination was conducted in $> 93\%$ of the total sample, the results of which showed high prevalence of lifetime substance use disorders (65%) and current major depressive disorder (MDD) (11%). As shown in Table 2, more SGA+ than SGA– participants had lifetime psychiatric diagnosis of substance use disorders (abuse or dependence; $\chi^2=6.47$, $df=1$, $P=0.011$) or alcohol use disorders (abuse or dependence; $\chi^2=3.95$, $df=1$, $P=0.047$), current MDD ($\chi^2=20.8$, $df=1$, $P<0.001$) and bipolar disorder ($\chi^2=28.6$, $df=1$, $P<0.001$).

HCV serostatus was associated with lower levels of TC (ES=−0.50) and LDL (ES=−0.58) (models not shown).

4. Discussion

This is the largest study to examine metabolic consequences of combining antiretroviral therapy and second-generation antipsychotic drugs in HIV-infected adults. Exposure to SGAs was independently associated with multiple components of the metabolic syndrome including increased plasma triglycerides (TG), elevated body mass index (BMI), higher mean arterial pressure (MAP) and increased prevalence of diabetes mellitus (DM). These findings represent compelling evidence that use of SGAs in HIV infected individuals increases the risk of hyperlipidemia, hypertension and diabetes, as seen with SGA use in HIV-*uninfected* persons (De Hert et al., 2009). This effect was independent of the use of antiretroviral medications associated with metabolic side effects.

The concern about metabolic risk is not limited to the use of SGAs, as both HIV infection and ART are associated with metabolic abnormalities. Increased serum triglycerides in untreated HIV infection may represent a consequence of the systemic inflammatory response to persistent HIV infection (Grunfeld and Feingold, 1992). Thus, some of metabolic abnormalities may be attributable to neither ART nor SGAs. Nevertheless, the thymidine analogue ART drugs are associated with dyslipidemia, insulin resistance and increased risk of DM (Carr, 2003; Ledergerber et al., 2007), as our analysis on zidovudine and stavudine confirm. Likewise, protease inhibitors have been linked to insulin resistance, dyslipidemia and central obesity possibly through increased mitochondrial oxidative stress (Penzak and Chuck, 2000). These atherogenic metabolic abnormalities probably contribute to the 26% increase in risk of heart disease for each year on cART (Friis-Moller et al., 2003).

Superimposed on this baseline level of metabolic risk in HIV patients, the use of SGAs is also known to be associated with an array of metabolic disturbances (Meyer, 2010). While data on quetiapine and risperidone in HIV uninfected patients with schizophrenia show lower risk for weight gain, elevated triglycerides and hyperglycemia compared to olanzapine and clozapine, there is no substantial data on use in treated HIV patients. In our cohort, quetiapine was the most frequently prescribed psychotropic medication, consistent with previous reports (Freudenreich et al., 2010), and quetiapine users had a higher proportion of DM, underlining a possible additive effect of ART when combined with SGAs. Risperidone was the only SGA for which longer exposure was statistically associated with higher odds of having DM.

The combined effects of ART and psychotropic medications in increasing adverse metabolic outcomes can be explained by one of several mechanisms, including competition for their metabolism by the same cytochrome P450 isoenzyme system (Singh and Goodkin, 2007) and direct biological effects at multiple loci. Many ARTs are potent inhibitors of cytochrome P450 enzymes, particularly CYP 3A4, and thereby increase serum concentrations of some antipsychotic drugs (e.g. quetiapine), leading to higher plasma antipsychotic levels and potentially more pronounced adverse effects (Singh and Goodkin, 2007; Thompson et al., 2006; Tseng and Foisy, 1999); however this pharmacokinetic interaction between ART and SGAs is not confirmed by literature that doesn't correlate plasma level of SGAs to metabolic side effects (Coe and Hong, 2012; Suzuki et al., 2011).

Both drug classes may decrease activity of the glucose transporter 4 in the myocyte cell membrane, leading to decreased glucose uptake, insulin resistance and hyperinsulinemia (Sathekge et al., 2010). Increased production of cytokines (Lihn et al., 2003; Pacenti et al., 2006) and mitochondrial toxicity in adipose tissue, both well-known side effects of ARTs, could induce adipocyte apoptosis (Buffet et al., 2005). Recent studies also have shown that chronic olanzapine treatment induces pro-inflammatory cytokine production, a risk factor for insulin resistance and cardiovascular disease (Victoriano et al., 2010). Both ARTs and SGAs disrupt adipogenesis in subcutaneous fat through alterations in the sterol regulatory enhancer-binding protein 1 (SREBP1) and peroxisome proliferator activated receptor gamma (PPAR- γ) resulting in elevated triglyceride and fatty acid levels which cause insulin resistance (Mallon et al., 2005), (Dresner et al., 1999; Hadigan et al., 2003). Lastly, ARTs and SGAs are associated with increased levels of TNF- α , a proinflammatory protein, and leptin, a hormone that regulates appetite and weight (Vergara-Rodriguez et al., 2009). The finding that SGAs are associated with hypertension is consistent with mediation through weight gain or direct binding effects on alpha 2 receptors by olanzapine and risperidone (Abi-Dargham and Laruelle, 2005).

The decision to examine the concurrent use of SGAs and ARTs in our study population was driven by data showing that a high proportion of HIV-infected people have a past or current psychiatric diagnosis (Burnam et al., 2001). The proportion of HIV-infected adults taking SGAs in this cohort (11%) was higher than previously reported (4.7%) (Vitiello et al., 2003), and may relate to an evolution in psychiatric practice as SGAs are applied more broadly to conditions such as major depression.

The role of ART factors and HCV comorbidity were both examined. As expected, HCV status was associated with lower levels of TC and LDL (model not shown), a finding consistent with other reports that HCV co-infection in HIV-infected adults appears to reduce the risk of cART- associated dyslipidemia (Cooper et al., 2007). Psychiatric comorbidity may have influenced ART choice since EFV-based ART regimens were less common in the SGA+ group. Avoidance of EFV may possibly be based on clinicians' reluctance to prescribe EFV to patients with psychiatric disorders because of this drug's frequent neuropsychiatric side effects such as intense dreams, depression and anxiety (Himelhoch et al., 2007) (Arendt et al., 2007). Regardless of the pattern of EFV use, the concomitant use of SGAs further increased metabolic risk as shown in the multivariable models.

This study has several limitations. We studied a sample of convenience, so the results may not be generalizable to the entire HIV-infected population. Because actively psychotic patients were excluded from most protocols comprising our sample, our participants may not be representative of all HIV-infected people taking antipsychotics (Lieberman et al., 2005). Although our HIV SGA+ cohort was more than twice as large as one previously described (Vitiello et al., 2003), the SGA+ cohort is still only 12% of the total sample (258 out of 2229 total subjects). Larger SGA+ samples may provide different estimates of the comparative metabolic impact versus an SGA- cohort. The absence of data on SGA dosing or plasma levels also omits an important aspect of SGA treatment that could influence metabolic risk. Our cross-sectional, observational design is vulnerable to biases including unmeasured confounders. Because of the retrospective nature of the study, baseline metabolic data was

not available prior to ART or SGA use. Although fasting laboratory measurements were not obtained, recent large studies have demonstrated that, for some variables (e.g. triglycerides), non-fasting values may be more important than fasting levels in cardiovascular risk assessment (Eckel et al., 2010; Nordestgaard et al., 2007; Sarwar et al., 2010), and for other, lipid levels, there is relatively limited variability between fasting and the nonfasting states (Langsted et al., 2008). Moreover measurement of nonfasting lipid fractions may also ultimately better predict cardiovascular disease risk (Mora et al., 2008), as more representative of human usual metabolic conditions (Expert Committee on the and Classification of Diabetes, 2003).

When combined ART and SGAs are necessary, we recommend a systematic approach to side effect monitoring. This is often neglected in clinical practice (Fleischhacker, 2009) (Haddad et al., 2014; Mitchell et al., 2012). When a clinical intervention is required, it should take into account that both nonpharmacological and pharmacological factors contribute to metabolic side effects (Megna et al., 2011). Nonpharmacological interventions include individual or group psychoeducation, self-monitoring, cognitive behavioral therapy, nutritional intervention, supervised exercise programs, and/or nutritionist and dietician consultations (Caemmerer et al., 2012; Gaughran and Lally, 2013). The first pharmacological intervention is to switch to a less orexigenic antipsychotic (Maayan and Correll, 2010), or to a different ART composition (Samaras, 2008), although the benefit of this change should be weighed against respectively potential worsening of psychopathology (Rosenheck et al., 2009) and drug toxicities/resistances (Samaras, 2008). Adjunctive pharmacological interventions could be targeted to specific metabolic alterations (e.g. fibrate therapy for hypertriglyceridaemia). Different agents (e.g. metformin, stimulants, reboxetine, topiramate) have been studied to prevent or reduce antipsychotics induced-weight gain with only limited evidence of efficacy (Maayan et al., 2010). Metformin could be effective in patients whose weight increases more than 10 kg after the first exposure to antipsychotics (Bjorkhem-Bergman et al., 2011). Additionally metformin was found to improve insulin sensitivity and reduce abdominal obesity in patients taking ART (van Wijk et al., 2005); metformin has limited gastrointestinal side effects and is not metabolized by hepatic P450 enzymes, so it could represent a valid option to avoid drug-drug interactions during concomitant use of ART and SGAs.

Despite these limitations, the findings presented here highlight the need for prospective longitudinal observational and interventional (treatment) studies of metabolic consequences of concurrent SGA and ART use in HIV-infected individuals to understand which combinations of ART drugs and SGAs produce the least metabolic effects and the methods to ameliorate these effects could improve the long-term health of these patients and reduce rates of cardiovascular mortality.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) is supported by awards N01 MH22005, HHSN271201000036C, and HHSN271201000030C from the National Institutes of Health.

The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) group is affiliated with the Johns Hopkins University, Mount Sinai School of Medicine, University of California, San Diego, University of Texas, Galveston, University of Washington, Seattle, Washington University, St. Louis and is headquartered at the University of California, San Diego and includes: Igor Grant, M.D. (UCSD, Director); Ronald J. Ellis, M.D., Ph.D. (UCSD, Co-Director); Scott L. Letendre, M.D. (UCSD, Co-Director); Ian Abramson, Ph.D. (UCSD, Co-Investigator); Muhammad Al-Lozi, M.D. (Washington University, Co-Investigator); J. Hampton Atkinson, M.D. (UCSD, Co-Investigator); Edmund Capparelli, Pharm.D. (UCSD, Co-Investigator); David Clifford, M.D. (Washington University, Site PI), Ann Collier, M.D. (University of Washington, Site Co-PI), Christine Fennema-Notestine, Ph.D. (UCSD, Core PI), Anthony C. Gamst, Ph.D. (UCSD, Core PI), Benjamin Gelman, M.D., Ph.D. (University of Texas, Site PI), Robert K. Heaton, Ph.D. (UCSD), Thomas D. Marcotte, Ph.D. (UCSD, Core PI), Christina Marra, M.D. (University of Washington, Site Co-PI), J. Allen McCutchan, M.D. (UCSD, Site PI), Justin McArthur, M.D. (Johns Hopkins, Site PI), Susan Morgello, M.D. (Mount Sinai, Site Co-PI), David Simpson, M.D. (Mount Sinai, Site Co-PI), Davey M. Smith, M.D. (UCSD, Core PI), Michael J. Taylor, Ph.D. (UCSD, Core Co-Investigator), Rebecca Theilmann, Ph.D. (UCSD, Imaging Physicist), Florin Vaida, Ph.D. (UCSD, Co-Investigator), Steven Paul Woods, Psy.D. (UCSD, Co-Investigator); Study Coordinators: Terry Alexander, R.N. (UCSD, Neuromedical Coordinator), Clint Cushman (UCSD, Data Manager), Matthew Dawson (UCSD, Neurobehavioral Coordinator), Donald Franklin, Jr. (UCSD, Center Manager), Eleanor Head, R.N., B.S.N. (University of Texas, Site Coordinator), Trudy Jones, M.N., A.R.N.P. (University of Washington, Site Coordinator), Jennifer Marquie-Beck, M.P.H. (UCSD, Recruitment Coordinator), Letty Mintz, N.P. (Mount Sinai, Site Coordinator), Vincent Rogalski, C.C.R.P. (Johns Hopkins, Site Coordinator), Mengesha Teshome, M.D. (Washington University, Site Coordinator), Will Toperoff, B.S., N.D. (UCSD, Site Coordinator).

The views expressed in this article are those of the authors and do not reflect the official policy or position of the United States Government.

References

- Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. *European Psychiatry*. 2005; 20:15–27. [PubMed: 15642439]
- Arendt G, de Nocker D, von Giesen HJ, Nolting T. Neuropsychiatric side effects of efavirenz therapy. *Expert Opinion on Drug Safety*. 2007; 6:147–154. [PubMed: 17367260]
- Atkinson JH Jr, Grant I, Kennedy CJ, Richman DD, Spector SA, McCutchan JA. Prevalence of psychiatric disorders among men infected with human immunodeficiency virus. A controlled study. *Archives of General Psychiatry*. 1988; 45:859–864. [PubMed: 3415427]
- Atkinson JH, Heaton RK, Patterson TL, Wolfson T, Deutsch R, Brown SJ, Summers J, Sciolla A, Gutierrez R, Ellis RJ, Abramson I, Hesselink JR, McCutchan JA, Grant I, Group H. Two-year prospective study of major depressive disorder in HIV-infected men. *Journal of Affective Disorders*. 2008; 108:225–234. [PubMed: 18045694]
- Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, Turner BJ, Eggan F, Beckman R, Vitiello B, Morton SC, Orlando M, Bozzette SA, Ortiz-Barron L, Shapiro M. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. *Archives of General Psychiatry*. 2001; 58:721–728. [PubMed: 11483137]
- Bjorkhem-Bergman L, Asplund AB, Lindh JD. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. *Journal of Psychopharmacology*. 2011; 25:299–305. [PubMed: 20080925]
- Blackburn P, Lemieux I, Lamarche B, Bergeron J, Perron P, Tremblay G, Gaudet D, Despres JP. Type 2 diabetes without the atherogenic metabolic triad does not predict angiographically assessed coronary artery disease in women. *Diabetes Care*. 2008; 31:170–172. [PubMed: 17934152]
- Buffet M, Schwarzsinger M, Amellal B, Gourelain K, Bui P, Prevot M, Deleuze J, Morini JP, Gorin I, Calvez V, Dupin N. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipodystrophy. *Journal of Clinical Virology*. 2005; 33:60–64. [PubMed: 15797366]
- Burnam MA, Bing EG, Morton SC, Sherbourne C, Fleishman JA, London AS, Vitiello B, Stein M, Bozzette SA, Shapiro MF. Use of mental health and substance abuse treatment services among

- adults with HIV in the United States. *Archives of General Psychiatry*. 2001; 58:729–736. [PubMed: 11483138]
- Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. *Schizophrenia Research*. 2012; 140:159–168. [PubMed: 22763424]
- Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. *AIDS*. 2003; 17(Suppl 1):S141–148. [PubMed: 12870540]
- Coe HV, Hong IS. Safety of low doses of quetiapine when used for insomnia. *Annals of Pharmacotherapy*. 2012; 46:718–722. [PubMed: 22510671]
- Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. *Preventing Chronic Disease*. 2006; 3:A42. [PubMed: 16539783]
- Cooper CL, Mills E, Angel JB. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection. *AIDS*. 2007; 21:71–76. [PubMed: 17148970]
- Cournos F, McKinnon K. HIV seroprevalence among people with severe mental illness in the United States: a critical review. *Clinical Psychology Review*. 1997; 17:259–269. [PubMed: 9160176]
- De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). *European Psychiatry*. 2009; 24:412–424. [PubMed: 19682863]
- Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. *The Journal of Clinical Investigation*. 1999; 103:253–259. [PubMed: 9916137]
- Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet*. 2010; 375:181–183. [PubMed: 20109902]
- Expert Committee on the, D. Classification of Diabetes, M. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2003; 26(Suppl 1):S5–20. [PubMed: 12502614]
- Falutz J. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. *Nature Clinical Practice Endocrinology & Metabolism*. 2007; 3:651–661.
- Feeney ER, Mallon PW. HIV and HAART-Associated Dyslipidemia. *The Open Cardiovascular Medicine Journal*. 2011; 5:49–63. [PubMed: 21643501]
- Fleischhacker WW. Tolerability of antipsychotics: recent controversies and future management. *Journal of Clinical Psychiatry*. 2009; 70:e06.
- Freudenreich O, Goforth HW, Cozza KL, Mimiaga MJ, Safren SA, Bachmann G, Cohen MA. Psychiatric treatment of persons with HIV/AIDS: an HIV-psychiatry consensus survey of current practices. *Psychosomatics*. 2010; 51:480–488. [PubMed: 21051679]
- Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD. Combination antiretroviral therapy and the risk of myocardial infarction. *New England Journal of Medicine*. 2003; 349:1993–2003. [PubMed: 14627784]
- Gaughran F, Lally J. Non-pharmacological interventions reduce antipsychotic-associated weight gain in outpatients. *Evidence-Based Mental Health*. 2013; 16:18. [PubMed: 23213120]
- Gaynes BN, Pence BW, Eron JJ Jr, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. *Psychosomatic Medicine*. 2008; 70:505–511. [PubMed: 18378865]
- Genuth S, Alberti KG, Bennett P, Buse J, DeFronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P, Expert Committee on the, D. Classification of Diabetes, M. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care*. 2003; 26:3160–3167. [PubMed: 14578255]

- Germinario RJ. Anti-retroviral protease inhibitors—‘a two edged sword?’. *IUBMB Life*. 2003; 55:67–70. [PubMed: 12749688]
- Girman CJ, Dekker JM, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ. An exploratory analysis of criteria for the metabolic syndrome and its prediction of long-term cardiovascular outcomes: the Hoorn study. *American Journal of Epidemiology*. 2005; 162:438–447. [PubMed: 16076828]
- Grigorescu M, Radu C, Crisan D, Grigorescu MD, Serban A, Neculoiu D, Rusu M, Acalovschi M. Metabolic syndrome, insulin resistance and adiponectin level in patients with chronic hepatitis C. *Journal of Gastrointestinal and Liver Diseases*. 2008; 17:147–154. [PubMed: 18568135]
- Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. *New England Journal of Medicine*. 1992; 327:329–337. [PubMed: 1620172]
- Haddad PM, Fleischacker WW, Peuskens J, Cavallaro R, Lean ME, Morozova M, Reynolds G, Azorin JM, Thomas P, Moller HJ. SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects. *Therapeutic Advances in Psychopharmacology*. 2014; 4:15–21. [PubMed: 24490026]
- Hadigan C, Rabe J, Meininger G, Aliabadi N, Breu J, Grinspoon S. Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution. *The American Journal of Clinical Nutrition*. 2003; 77:490–494. [PubMed: 12540412]
- Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. *American Journal of Psychiatry*. 1996; 153:1195–1201. [PubMed: 8780425]
- Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV, Team ACTGAS. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. *AIDS*. 2009; 23:1109–1118. [PubMed: 19417580]
- Himelhoch S, Powe NR, Breakey W, Gebo KA. Schizophrenia, AIDS and the decision to prescribe HAART: results of a national survey of HIV clinicians. *Journal of Prevention and Intervention in the Community*. 2007; 33:109–120. [PubMed: 17298934]
- Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. *Circulation*. 2008; 118:2047–2056. [PubMed: 18955664]
- Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, Cavassini M, Bernasconi E, Schmid P, Egger M, Weber R, Swiss HIVCS. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. *Clinical Infectious Diseases*. 2007; 45:111–119. [PubMed: 17554711]
- Lee S, Rothbard AB, Noll E, Blank MB. Use of HIV and psychotropic medications among persons with serious mental illness and HIV/AIDS. *Administration and Policy in Mental Health*. 2011; 38:335–344. [PubMed: 20976619]
- Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, Bergeron J, Gaudet D, Tremblay G, Prud'homme D, Nadeau A, Despres JP. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? *Circulation*. 2000; 102:179–184. [PubMed: 10889128]
- Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Investigators, C. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *New England Journal of Medicine*. 2005; 353:1209–1223. [PubMed: 16172203]
- Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, Madsbad S, Andersen O. Increased expression of TNF- α , IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. *The American Journal of Physiology, Endocrinology and Metabolism*. 2003; 285:E1072–1080.
- Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. *Gastroenterology*. 2004; 126:586–597. [PubMed: 14762795]

- Maayan L, Correll CU. Management of antipsychotic-related weight gain. *Expert Review of Neurotherapeutics*. 2010; 10:1175–1200.
- Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. *Neuropsychopharmacology*. 2010; 35:1520–1530. [PubMed: 20336059]
- Mallon PW, Unemori P, Sedwell R, Morey A, Rafferty M, Williams K, Chisholm D, Samaras K, Emery S, Kelleher A, Cooper DA, Carr A, Investigators S. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. *Journal of Infectious Disease*. 2005; 191:1686–1696.
- Mannucci E, Monami M, Cresci B, Pala L, Bardini G, Petracca MG, Dicembrini I, Pasqua A, Buiatti E, Rotella CM. National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the Firenze-Bagno A Ripoli study. *Diabetes Obesity and Metabolism*. 2008; 10:430–435.
- McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. *Schizophrenia Research*. 2005; 80:19–32. [PubMed: 16137860]
- Megna JL, Schwartz TL, Siddiqui UA, Herrera Rojas M. Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions. *Annals of Clinical Psychiatry*. 2011; 23:131–140. [PubMed: 21547274]
- Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. *Annals of Internal Medicine*. 2000; 133:592–599. [PubMed: 11033586]
- Meyer JM. Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C-seropositive state hospital patients: results from Oregon State Hospital. *Journal of Clinical Psychiatry*. 2003; 64:540–545. [PubMed: 12755656]
- Meyer JM. Antipsychotics and metabolics in the post-CATIE era. *Current Topics in Behavioral Neurosciences*. 2010; 4:23–42. [PubMed: 21312396]
- Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. *Acta Psychiatrica Scandinavica*. 2009; 119:4–14. [PubMed: 19133915]
- Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. *Psychological Medicine*. 2012; 42:125–147. [PubMed: 21846426]
- Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. *Circulation*. 2008; 118:993–1001. [PubMed: 18711012]
- Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. *Liver International*. 2009; 29:26–37. [PubMed: 19187070]
- Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. *Drugs*. 2003; 63:2555–2574. [PubMed: 14636077]
- Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. *JAMA*. 2007; 298:299–308. [PubMed: 17635890]
- Pacenti M, Barzon L, Favaretto F, Fincati K, Romano S, Milan G, Vettor R, Palu G. Microarray analysis during adipogenesis identifies new genes altered by antiretroviral drugs. *AIDS*. 2006; 20:1691–1705. [PubMed: 16931933]
- Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: Pathophysiology, prevalence, risk factors and treatment. *Scandinavian Journal of Infectious Diseases*. 2000; 32:111–123. [PubMed: 10826894]
- Rabkin JG. HIV and depression: 2008 review and update. *Current HIV/AIDS Reports*. 2008; 5:163–171. [PubMed: 18838056]
- Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA, et al. The Composite International Diagnostic Interview. An epidemiologic instrument

- suitable for use in conjunction with different diagnostic systems and in different cultures. *Archives of General Psychiatry*. 1988; 45:1069–1077. [PubMed: 2848472]
- Romero-Gomez M. Insulin resistance and hepatitis C. *World Journal of Gastroenterology*. 2006; 12:7075–7080. [PubMed: 17131467]
- Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, McEvoy J, Lieberman J. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. *Schizophrenia Research*. 2009; 107:22–29. [PubMed: 18993031]
- Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? *Archives of General Psychiatry*. 2007; 64:1123–1131. [PubMed: 17909124]
- Samaras K. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. *Journal of Antimicrobial Chemotherapy*. 2008; 61:238–245.
- Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. *Lancet*. 2010; 375:1634–1639. [PubMed: 20452521]
- Sathekge M, Maes A, Kgomo M, Stolz A, Ankrah A, Van de Wiele C. Evaluation of glucose uptake by skeletal muscle tissue and subcutaneous fat in HIV-infected patients with and without lipodystrophy using FDG-PET. *Nuclear Medicine Communications*. 2010; 31:311–314. [PubMed: 20145581]
- Singh D, Goodkin K. Psychopharmacologic treatment response of HIV-infected patients to antipsychotic medications. *Journal of Clinical Psychiatry*. 2007; 68:631–632. [PubMed: 17474821]
- Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. *Archives of General Psychiatry*. 1992; 49:624–629. [PubMed: 1637252]
- Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? *Acta Psychiatrica Scandinavica*. 2009; 119:171–179. [PubMed: 19178394]
- Suzuki Y, Ono S, Sugai T, Fukui N, Watanabe J, Tsuneyama N, Sawamura K, Someya T. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia. *Human Psychopharmacology*. 2011; 26:440–443. [PubMed: 21823168]
- Thompson A, Silverman B, Dzen L, Treisman G. Psychotropic medications and HIV. *Clinical Infectious Diseases*. 2006; 42:1305–1310. [PubMed: 16586391]
- Tseng AL, Foisy MM. Significant interactions with new antiretrovirals and psychotropic drugs. *Annals of Pharmacotherapy*. 1999; 33:461–473. [PubMed: 10332538]
- van Wijk JP, de Koning EJ, Cabezas MC, op't Roodt J, Joven J, Rabelink TJ, Hoepelman AI. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. *Annals of Internal Medicine*. 2005; 143:337–346. [PubMed: 16144892]
- Vergara-Rodriguez P, Vibhakar S, Watts J. Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human immunodeficiency virus and severe mental illness. *Pharmacology and Therapeutics*. 2009; 124:269–278. [PubMed: 19647020]
- Victoriano M, de Beaupaire R, Naour N, Guerre-Millo M, Quignard-Boulange A, Huneau JF, Mathe V, Tome D, Hermier D. Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state. *Brain Research*. 2010; 1350:167–175. [PubMed: 20570665]
- Vitiello B, Burnam MA, Bing EG, Beckman R, Shapiro MF. Use of psychotropic medications among HIV-infected patients in the United States. *American Journal of Psychiatry*. 2003; 160:547–554. [PubMed: 12611837]
- Vittinghoff, E.; Glidden, DV.; McCulloch, CE.; Shiboski, SC.; SpringerLink (Online service). *Regression Methods in Biostatistics Linear, Logistic, Survival, and Repeated Measures Models, Statistics for biology and health*. Springer Science+Business Media, Inc.; New York, NY: 2005.
- Walkup JT, Sambamoorthi U, Crystal S. Use of newer antiretroviral treatments among HIV-infected medicaid beneficiaries with serious mental illness. *Journal of Clinical Psychiatry*. 2004; 65:1180–1189. [PubMed: 15367044]

Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. *Archives of Internal Medicine*. 2005; 165:2644–2650. [PubMed: 16344423]

Table 1

Demographic and Clinical Characteristics of 2,229 HIV-infected Participants on cART

Demographics		Age (years) ¹	Gender (male) ²	SGA- (n=1971)	SGA+ (n=258)	p-value
				455 (94)	453 (80)	ns
				1613 (82%)	194 (75%)	0013*
		Black		619 (31%)	103 (40%)	0007*
		Hispanic		350 (18%)	32 (12%)	0040*
		White		936 (47%)	114 (44%)	ns
		Others		66 (3%)	9 (4%)	ns
Clinical	HIV disease status	Estimated duration of HIV infection (months) ¹		146 (82)	148 (86)	ns
		Nadir CD4 (cells/mm ³) ³		113 (26–232)	147 (40–226)	ns
		Current CD4 (cells/mm ³) ³		439 (258–6445)	425 (258–615)	ns
		Current Plasma VL (log ₁₀ c/mL) ³		17 (17–24)	17 (17–26)	ns
		Duration of current regimen (months) ³		152 (54–43)	163 (69–18)	ns
Antiretroviral Therapy		PI-based (%) ²		1233 (63%)	170 (66%)	ns
		EFV-based (%) ²		507 (26%)	46 (18%)	0007*
		Hepatitis C Virus status, (% positive) ²		281 (14%)	47 (18%)	ns

¹ Mean (standard deviation)

² Number (%)

³ Median (Inter-quartile Range)

* p-value from Chi-square test

All percentages based on the complete (non-missing) data only **Age**: N (%) missing: 0; **Gender** N (%) missing: 0; **Ethnicity** N (%) missing: 0; **Estimated duration of HIV infection**, N (%) unknown: 117 (52%); **Nadir CD4**, N (%) missing: 230 (103%); **Current CD4**, N (%) missing: 45 (2%); **Current Plasma VL**, N (%) missing: 213 (96%); **Duration of current ART regimen** N (%) missing: 106 (48%); **Diagnosis of Diabetes Mellitus**, N (%) missing: 316 (142%); **BMI**, N (%) missing: 101 (45%); **HCV** serostatus, N (%) missing: 0

Table 2

Psychiatric diagnoses and exposures to SGAs

		SGA– (n=1971)	SGA+ (n=258)	p-value
Psychiatric diagnosis	Current substance abuse/dependence ^{1#}	97 (5%)	17 (7%)	ns
	Lifetime substance abuse/dependence ^{1#}	1265 (69%)	186 (78%)	0011 *
	Alcohol abuse/dependence ^{1#}	944 (52%)	141 (59%)	0047 *
	Current major depressive disorder (MDD) ^{1#}	198 (11%)	51 (22%)	<0001 *
	Bipolar Disorder ^{1#}	53 (24%)	47 (57%)	<0001 *
SGA Use	Daily dose for most commonly used SGAs (mg) ²			
	Aripiprazole (N=14)		124 (96)	
	Olanzapine (N=43)		142 (119)	
	Quetiapine (N=81)		241 (276)	
	Risperidone (N=29)		23 (16)	
	Ziprasidone (N=6)		123 (144)	
	Duration of current treatment, months ³		159 (5–363)	

¹ Number (%),[#] percentages based on non-missing data only Current substance abuse/dependence: N (%) missing 231(10%); Lifetime substance abuse/dependence N (%) missing 163 (7%); Alcohol abuse/dep: N (%) missing 163 (7%); Current major depressive disorder (MDD): N (%) missing 232 (10%); Bipolar Disorder: N (%) missing 1926 (86%);² Mean (standard deviation), Daily dose: N (%) missing 83 (32%);³ Median (Inter-quartile Range) Duration of current treatment: N (%) missing 14 (5%)

* p-value from Chi-square test

Table 3
Multivariable analyses of correlates of metabolic variables affected by second generation antipsychotic drugs

All correlates presented in the table were included in the models of the effects of correlates on each metabolic variable Effect size (ES) is expressed in Cohen's d for body mass index (BMI), mean arterial pressure (MAP), triglycerides (TG) Effect size is expressed as adjusted odds ratio for diabetes mellitus (DM) 95% confidence intervals are in parentheses Sample sizes were for BMI, N=1527; MAP, N=1051; TG, N=985; DM, N=1051

Metabolic variable	BMI	MAP	TG ¹	DM
Correlate				
SGA	016* (-001, 033)	028*** (008, 049)	028** (006, 1 050)	228*** (129, 402)
Age ²		011*** (004, 019)		162*** (130, 203)
Male	-045*** (-058, -032)	028*** (013, 044)	028*** (012, 044)	
Ethnicity³				
White	-008 (-020, 003)	-026*** (-040, -012)	036*** (022, 051)	
Hispanic	005 (-011, 021)	-036*** (-055, -018)	050*** (031, 069)	
Other	-042** (-73, -011)	-040** (-073, -006)	022 (-015, 060)	
Hepatitis C Virus status				197** (123, 215)
Estimated HIV duration (years) ⁴		005** (0, 010)		
CD4 nadir ⁵			-005* (-01, 0)	
CD4 ⁵	004*** (002, 005)		004*** (002, 006)	106* (100, 113)
Detectable plasma viral load				
Protease inhibitor-based regimen	-010* (-021, 0)	-018*** (- 031, -006)	019*** (006, 032)	
Life-time substance dependence diagnosis	-011* (-022, 0)			

Notes:

* $p < 010$,

** $p < 005$,

*** $p < 001$

¹ TG values were log transformed

² ES per 10 years increase

³ Reference group is black

⁴ ES per 5 year increase

⁵ES per 100 cell count increase